

Determining the degree of adherence to treatment in inflammatory bowel disease patients

Hedieh Balaii¹, Sepideh Olyanasab Narab², Binazir Khanabadi³, Fakhri Alsadat Anaraki⁴, Shabnam Shahrokh²

¹ Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

² Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

³ Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

⁴Colorectal Division of Surgical Ward, Taleghani Hospital, Shahid Beheshti University of Medical Science, Tehran, Iran

ABSTRACT

Aim: Since the inflammatory bowel disease (IBD) is a disorder which requires continuous drug intake to induce and maintain the remission phase, finding the barriers for low adherent group, may improve the disease phase and quality of life in those patients.

Background: IBD is defined as a chronic immune disorder with unpredictable flares. The common treatment of these diseases can be effective for inducing and maintaining remission courses. Therefore the use of long-term medication therapy is the crucial key to prevent surgery and complications in patients with IBD.

Methods: Morisky Medication Adherence Scales (MMAS) is used for detecting level of adherence to the medicines for 137 patients with IBD. Demographic and clinical data are recorded for all patients and quality of life has been evaluated by Short-Form 36 questionnaire in 55 patients.

Results: Demographic and clinical features showed no correlation with the degree of adherence. The MMAS-8 score in the low adherent group significantly different than that in the medium and high adherer group. No relation was found statistically between level of adherence and mental or physical sates (p value=0.17, 1.2) and total quality of life (p value=0.22) in patients with IBD.

Conclusion: Designing smart reminder and the physician's explain about adverse effects and beneficial of medicines may be effective to confront with forgetfulness and feeling comfort with treatment. Improve a strategy in order to regular measurement of adherence to medication, provides enough information about stop taking medication.

Keywords: Inflammatory bowel disease, Ulcerative colitis, Crohn's disease, Adherence, Quality of life.

(Please cite as: **Balaii H, Olyanasab Narab S, Khanabadi B, Alsadat Anaraki F, Shahrokh SH. Determining the degree of adherence to treatment in inflammatory bowel disease patients. Gastroenterol Hepatol Bed Bench 2018;11(Suppl. 1):S39-S44.**)

Introduction

The inflammatory bowel disease (IBD) encompassing Crohn's disease (CD) and ulcerative colitis (UC) is defined as chronic immune disorders with unpredictable flare (1, 2). The common treatment

of these diseases: mesalamine-based compounds, corticosteroids, thiopurines, and anti-TNF therapies can be effective for inducing and maintaining remission (3, 4). Therefore, the use of long-term medication therapy is the crucial key to prevent surgery and complications in patients with IBD. Poor management of disease may contribute to low adherence associated with increasing the risk of relapses, colorectal cancer and eventually mortality and a decreased quality of life (5-7). Low adherence to medication has been reported in previous studies rating 40-72% in individuals suffering from

Received: 13 August 2018 Accepted: 18 November 2018

Reprint or Correspondence: Shabnam Shahrokh, MD, Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

E-mail: shabnamshahrokh@gmail.com

ORCID ID: 0000-0002-3420-5608

S40 Degree of adherence to treatment in inflammatory bowel disease

IBD, resulting exacerbations of the disease (3, 5, 7-10). A high adherence would be achievable by enough information about continuous therapy and follow-ups due to a good cooperation between physician and patient (11, 12). Identifying the barriers leading to non-adherence to the drugs, can address to provide appropriate educational needs for IBD patients (13, 14). The term “compliance” has been expressed by Sackett and Haynes, which is associated with patient’s obedience to prescribed medicine and improved regimens and quality of life (15-17). On the other hand the exact goal of drug submission has been proposed by the term “adherence”, which is used to explain a deeper meaning of follow-up than compliance (18). The aim of this study was to determine the accurate measurements of adherence in IBD patients in order to seek the factors which accompany the flare-ups episodes.

Methods

The study protocol approval has been confirmed by the Ethics Committee of Shahid Beheshti Medical University. The participants were included to this study, if:

- i. they had a diagnosis of IBD approved by clinical, endoscopic, radiologic, and histopathologic criteria (19);
- ii. they were receiving medicine for their IBD by a gastroenterologist;
- iii. they were able to use oral drugs for IBD
- iv. They took medicine for IBD up to six months.

The patients younger than age 15 and new patients are excluded from the study. Morisky Medication Adherence Scales (MMAS), an 8-question questionnaire, has been validated and used for obtaining level of adherence to the medications (20). Each question scored one point if the answer was “no” in questions 1–4 and 6–7, while the answer “yes” in question 5 added-up one point. The question 8 is scored regarding to the four type of answers (rarely/never: 1.00; once in a while: 0.75; sometimes: 0.50; usually: 0.25; always: 0). The MMAS scores were categorized previously into the following three levels of adherence: high adherence (score: 8), medium adherence (score: 6-7), and low adherence (score: fewer than 6) (21).

In addition, another questionnaire has been designed in order to gather demographic and clinical

data, comprising age, gender, marital status, educational level, type of IBD, duration of disease, time for therapy, surgery related to IBD, type of medication, disease phase and behavior according to the Harvey-Bradshaw Index (HBI) disease activity scale for all patients. Quality of life has been evaluated by Short-Form 36 questionnaire (SF-36) in fifty-five patients.

Statistical analysis was calculated using Kruskal Wallis and One-Way ANOVA tests with $p \leq 0.05$ considered significant. All calculations were performed using SPSS 21.0 for Windows (SPSS, Inc, Chicago, IL).

Results

A total of 137 patients with IBD (35 CD, 102 UC) participated in the study. The characteristics of these patients are described in Table 1. Different factors such as gender, age, education, marital status, medication, disease behavior, time since diagnosis of IBD, or duration of disease and colectomy did not correlate with the degree of adherence. Also, according to our data, having CD tends to increase the therapeutic adherence to drugs, but these results were not statistically significant. There was also no association between non-adherence and disease type ($p = 0.69$), and clinical activity of disease in UC and CD patients ($p = 0.30, 0.21$) (Table 2).

Based on MMAS-8 responses, we identified 63 (46%) patients as low adherers and 57 (41.6%) patients as medium and 17 (12.4%) high adherers. The MMAS-8 score in the low adherer group was significantly different from that of medium and high adherer group ($p < 0.001$).

Fifty-five SF-36 questionnaires were answered by patients, but no relation was found statistically between level of adherence and mental or physical states (p value=0.17, 1.2) and total quality of life (p value=0.22) in patients with IBD.

The main reasons for non-adherence included forgetfulness 42 (50.6%) and feeling hassled about treatments 48 (57.8%).

Discussion

A successful treatment accompanies with a good cooperation between physician and patient, in order to achieve the best way to control the disease. The more

Table 1. Characteristics of 137 patients with IBD

Characteristics		N = 137 (%)
Diagnosis	Ulcerative Colitis	102 (74.5)
	Crohn' s Disease	35 (25.5)
Age (years)	Mean ± SD	33.30 ± 11.66
	Minimum, maximum	15 , 74
	≤30	66 (48.2)
Gender (%)	>30	71 (51.8)
	Male	40 (48.2)
Marital status	Female	71 (51.8)
	Single	57 (41.6)
Education	Married	78 (56.9)
	Divorced	2 (1.5)
	Illiterate	1 (0.7)
Disease behavior	Primary School	14 (10.2)
	High School	56 (40.9)
	Bachelor of Sciences	38 (28.7)
	Master of Sciences	11 (8)
	MD., PhD.	4 (2.9)
	Other	12 (8.8)
	Proctitis	13 (9.5)
	Left sided colitis	21 (15.3)
	Pancolitis	36 (26.3)
	UC + PSC	10 (7.3)
	UC Remission	37 (27.2)
	Penetrating CD	12 (8.8)
Medications	Strictureal CD	3 (2.2)
	Inflammatory CD	14 (10.2)
	Penetrating+ Strictureal CD	3 (2.2)
	CD Remission	11 (8.1)
	5-ASA	39 (28.5)
	Immunosuppressant	2 (1.5)
	Anti-TNF	6 (4.4)
Surgery	5-ASA+ Immunosuppressant	38 (27.7)
	5-ASA+ Anti-TNF	16 (11.7)
	Immunosuppressant+ Anti-TNF	4 (2.9)
	5-ASA+ Immunosuppressant+ Anti-TNF	31 (22.6)
Time from onset	UC Colectomy	4 (2.9)
	CD Colectomy	1 (0.7)
	<1 yeas	18 (13.1)
Time from diagnosis	1-5 years	43 (31.4)
	>5 years	39 (47)
	<1 yeas	26 (19)
	1-5 years	47 (34.3)
	>5 years	70 (51.1)

training of the patient regarding the correct use of the drugs and treatment follow-ups would be more desirable. Therefore, seeking obstacles associated with non-adherence may present better solutions for physicians and assistants to improve appropriate drug usage.

The rate of adherence is significantly low in our country comparing to other populations. (2, 8, 22-24)

In some studies a significant correlation is found between degree of adherence and age, gender, educational level, stable affective relationship, types of

treatment, disease type, extension and severity, duration of disease and onset and history of colectomy.(18, 22, 25, 26) But in our data, no association revealed between adherence level and mentioned features in accordance with other experience. (10, 27, 28)

Moreover, depression which is known as low adherence trigger in some investigations (18, 23), as well as physical quality of life in patients with IBD do not seem to be impressive in our study.

The standpoint of barriers associated with low-adherents were feeling hassled about treatments and

S42 Degree of adherence to treatment in inflammatory bowel disease

Table 2. Correlations between adherence degrees and participant endorsed barriers to medication adherence

		low-adherer	medium-adherer	high-adherer	p-value
UC		46 (45.1)	44 (43.1)	12 (11.8)	0.80
CD		17 (48.6)	13 (37.1)	5 (14.3)	
Age ≤30		32 (48.5)	26 (39.4)	8 (12.1)	0.84
Age >30		31 (43.7)	31 (43.7)	9 (12.7)	
Male		27 (38.0)	36 (50.7)	8 (11.3)	0.07
Female		36 (54.5)	21 (31.8)	9 (13.6)	
Single		27 (47.4)	23 (40.4)	7 (12.3)	0.50
Married		35 (44.9)	34 (43.6)	9 (11.5)	
Divorced		1 (50.0)	0	1 (50.0)	
Illiterate		1 (100)	0	0	0.91
Primary School		6 (42.9)	6 (42.9)	2 (14.3)	
High School		29 (51.8)	19 (33.9)	8 (14.3)	
Bachelor of Sciences		16 (42.1)	19 (50)	3 (7.9)	
Master of Sciences		6 (54.5)	4 (36.4)	1 (9.1)	
Other		4 (33.3)	6 (50)	2 (16.7)	
MD, PhD		1 (25)	2 (50)	1 (25)	
Proctitis		8 (61.5)	4 (30.8)	1 (7.7)	0.62
Left sided colitis		6 (28.6)	12 (57.1)	3 (14.3)	
Pancolitis		19 (52.8)	16 (44.4)	1 (2.8)	
Penetrating CD		5 (41.7)	5 (41.7)	2 (16.7)	
Strictureal CD		1 (33.3)	1 (33.3)	1 (33.3)	
Inflammatory CD		7 (50)	5 (35.7)	2 (14.3)	
Penetrating+ Strictureal CD		1 (33.3)	2 (66.7)	0	
UC+PSC		5 (50)	3 (30)	2 (20)	0.42
UC	Flare-up	32 (31.7)	27 (26.7)	5 (5.0)	0.30
	Remission	14 (13.9)	17 (16.8)	6 (5.9)	
CD	Flare-up	10 (28.6)	9 (25.7)	5 (14.3)	0.21
	Remission	7 (20)	4 (11.4)	0	
5-ASA		20 (51.3)	14 (35.9)	5 (12.8)	0.18
IM		0	2 (100)	0	
Anti-TNF		2 (33.3)	1 (16.7)	3 (50)	
5-ASA+ IM		20 (52.6)	16 (42.1)	2 (5.3)	
5-ASA+ Anti-TNF		8 (50)	7 (43.8)	1 (6.3)	
IM+ Anti-TNF		1 (25)	2 (50)	1 (25)	
5-ASA+ IM+Anti-TNF		11 (35.5)	15 (48.4)	5 (16.1)	
UC Colectomy		0	4 (4.0)	0	0.06
CD Colectomy		1 (2.9)	0	0	0.58
Time from Onset	<1 yeas	6 (33.3)	10 (55.6)	2 (11.1)	0.77
	1-5 years	20 (46.5)	18 (41.9)	5 (11.6)	
	>5 years	60 (45.8)	55 (42)	16 (12.2)	
Time from Diagnosis	<1 yeas	8 (30.8)	14 (53.8)	4 (15.4)	0.55
	1-5 years	23 (48.9)	19 (40.4)	5 (10.6)	
	>5 years	29 (50)	22 (37.9)	7 (12.1)	

forgetfulness, respectively similar to other authors (29-31). In summary, we resulted a low rate of adherence in our IBD patients associated with forgetfulness and feeling dissatisfied during a long time. Therefore, designing smart reminder on patient's phone would be effective to confront forgetfulness. In addition, the physician should spend more time on investigation, so that the patient gets more information about adverse effects of drugs and may be convinced that remission phase is dependent on regular treatment. Moreover,

regular evaluation of adherence to medication would be beneficial to follow-up.

Furthermore, assessment of a comprehensive system with more accurate questions to measure the adherence between IBD patients may improve the knowledge of adherence.

Conflict of interests

The authors declare that they have no conflict of interest.

References

1. Sewitch MJ, Abrahamowicz M, Barkun A, Bitton A, Wild GE, Cohen A, et al. Patient nonadherence to medication in inflammatory bowel disease. *AJG* 2003;98:1535-44.
2. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. *AJM* 2003;114:39-43.
3. Dadaei T, Safapoor MH, Asadzadeh Aghdaei H, Balaii H, Pourhoseingholi MA, Naderi N, et al. Effect of vitamin D3 supplementation on TNF- α serum level and disease activity index in Iranian IBD patients. *Gastroenterol Hepatol Bed Bench.* 2015;8:49-55.
4. Higgins PD, Rubin D, Kaulback K, Schoenfield P, Kane S. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. *Aliment Pharmacol Ther* 2009;29:247-57.
5. Taghipour N, Molaei M, Mosaffa N, Rostami-Nejad M, Asadzadeh Aghdaei H, Anissian A, et al. An experimental model of colitis induced by dextran sulfate sodium from acute progresses to chronicity in C57BL/6: correlation between conditions of mice and the environment. *Gastroenterol Hepatol Bed Bench.* 2016;9:45-52.
6. Kane SV, Sumner M, Solomon D, Jenkins M. Twelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: results from a large pharmacy prescriptions database. *Digest Dis Sci* 2011;56:3463-70.
7. Ingerski LM, Baldassano RN, Denson LA, Hommel KA. Barriers to oral medication adherence for adolescents with inflammatory bowel disease. *J Pediatr Psychol* 2009;35:683-91.
8. Taghipour N, Aghdaei HA, Haghighi A, Mossafa N, Tabaei SJ, Rostami-Nejad M. Potential treatment of inflammatory bowel disease: a review of helminths therapy. *Gastroenterol Hepatol Bed Bench.* 2014;7:9-16.
9. Rostami Nejad M, Ishaq S, Al Dulaimi D, Zali MR, Rostami K. The role of infectious mediators and gut microbiome in the pathogenesis of celiac disease. *Arch Iran Med.* 2015;18:244-49.
10. Trindade AJ, Ehrlich A, Kornbluth A, Ullman TA. Are your patients taking their medicine? Validation of a new adherence scale in patients with inflammatory bowel disease and comparison with physician perception of adherence. *Inflamm Bowel Dis* 2011;17:599-604.
11. Bermejo F, Román AL-S, Algaba A, Guerra I, Valer P, García-Garzón S, et al. Factors that modify therapy adherence in patients with inflammatory bowel disease☆. *J Crohns Colitis* 2010;4:422-6.
12. Greenley RN, Kunz JH, Biank V, Martinez A, Miranda A, Noe J, et al. Identifying youth nonadherence in clinical settings: data-based recommendations for children and adolescents with inflammatory bowel disease. *Inflamm Bowel Dis* 2011;18:1254-9.
13. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. *Nature clinical practice Gastroenterol Hepatol* 2006;3:390-407.
14. Tiao DK, Chan W, Jeganathan J, Chan JT, Perry J, Selinger CP, et al. Inflammatory Bowel Disease Pharmacist Adherence Counseling Improves Medication Adherence in Crohn's Disease and Ulcerative Colitis. *Inflamm Bowel Dis* 2017;23:1257-61.
15. Bhatt J, Patil S, Joshi A, Abraham P, Desai D. Self-reported treatment adherence in inflammatory bowel disease in Indian patients. *Indian J Gastroenterol* 2009;28:143-6.
16. Chan W, Chen A, Tiao D, Selinger C, Leong R. Medication adherence in inflammatory bowel disease. *Intest Res* 2017;15:434-45.
17. Robinson A. Improving adherence to medication in patients with inflammatory bowel disease. *Aliment Pharmacol Ther* 2008;27 s1:9-14.
18. San Román AL, Bermejo F, Carrera E, Pérez-Abad M, Boixeda D. Adherence to treatment in inflammatory bowel disease. *Rev Esp Enferm Dig* 2005;97:249-57.
19. Lennard-Jones J. Classification of inflammatory bowel disease. *Scan Journal Gastroentero* 1989;24 sup170:2-6.
20. Moharamzad Y, Saadat H, Nakhjavan Shahraki B, Rai A, Saadat Z, Aerab-Sheibani H, et al. Validation of the Persian Version of the 8-Item Morisky Medication Adherence Scale (MMAS-8) in Iranian Hypertensive Patients. *Glob J Health Sci* 2014;7:173-83.
21. Krousel-Wood M, Islam T, Webber LS, Re R, Morisky DE, Muntner P. New medication adherence scale versus pharmacy fill rates in hypertensive seniors. *Am J Manag care* 2009;15:59.
22. Kane SV, Robinson A. understanding adherence to medication in ulcerative colitis—innovative thinking and evolving concepts. *Aliment Pharmacol Ther* 2010;32:1051-8.
23. Sewitch MJ, Abrahamowicz M, Bitton A, Daly D, Wild GE, Cohen A, et al. Psychological distress, social support, and disease activity in patients with inflammatory bowel disease. *Am J gastroenterol* 2001;96:1470-9.
24. Karbalaee R, Piran M, Rezaei-Tavirani M, Asadzadeh-Aghdaei H, Heidari MH. A systems biology analysis protein-protein interaction of NASH and IBD based on comprehensive gene information. *Gastroenterol Hepatol Bed Bench.* 2017;10:194-201.
25. Červený P, Bortlík M, Kuběna A, Vlček J, Lakatos PL, Lukáš M. Nonadherence in inflammatory bowel disease: results of factor analysis. *Inflamm Bowel Dis* 2007;13:1244-9.
26. Kim SB, Kim KO, Jang BI, Kim ES, Cho KB, Park KS, et al. Patients' beliefs and attitudes about their treatment for inflammatory bowel disease in Korea. *J Gastroenterol Hepatol* 2016;31:575-80.
27. Bucci C, Zingone F, Tammaro S, Iovino P, Santonicola A, Ciacci C. Factors predicting the adherence to the therapy of Italian IBD patients. *Gastroenterol Res Pract* 2017;2017.

S44 Degree of adherence to treatment in inflammatory bowel disease

28. Ghadir MR, Bagheri M, Vahedi H, Daryani NE, Malekzadeh R, Hormati A, et al. Nonadherence to Medication in Inflammatory Bowel Disease: Rate and Reasons. *Middle East J Dig Dis* 2016;8:116.

29. Burgess SW, Sly PD, Morawska A, Devadason SG. Assessing adherence and factors associated with adherence in young children with asthma. *Respirology* 2008;13:559-63.

30. Marhefka SL, Koenig LJ, Allison S, Bachanas P, Bulterys M, Bettica L, et al. Family experiences with pediatric antiretroviral therapy: responsibilities, barriers, and strategies for remembering medications. *AIDS Patient Care STDS* 2008;22:637-47.

31. Zelikovsky N, Schast AP. Eliciting accurate reports of adherence in a clinical interview: development of the Medical Adherence Measure. *Pediatr Nurs* 2008;34.